High-engraftment efficiency of human cells in NOD/SCID/γ$cnull$ mice.

(A) Rates of human cells in peripheral blood from NOD/SCID/γ$cnull$ and NOD/Shi-scid mice with or without anti-asialo GM1 antibody 4 weeks after intravenous transfer of human CB CD34⁺ cells are shown. Some NOD/Shi-scid mice were treated with anti-asialo GM1 antibody immediately before cell transplantation. Percentage human CD45⁺ cells in mouse peripheral blood was assayed by flow cytometry. AGM indicates anti-asialo GM1 antibody. Asterisks indicate significant difference (P < .01) between data columns marked * and **. (B) Numbers of human cells in ascites from NOD/SCID/γ$cnull$ and NOD/Shi-scid mice with or without anti-asialo GM1 antibody 2 weeks after intraperitoneal transplantation of human PBMNCs are shown. Numbers of human CD45⁺ cells in ascites were calculated after flow cytometry. Antibody treatment was performed 1 day before cell transplantation in the same manner as CB CD34⁺ cell transplantation. Asterisks indicate significant difference (P < .01) between data columns marked * and **.